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Abstract
Aim: To better understand the marked decrease in serum triglycerides observed with
tirzepatide in patients with type 2 diabetes, additional lipoprotein-related biomarkers
were measured post hoc in available samples from the same study.
Materials and Methods: Patients were randomized to receive once-weekly subcuta-
neous tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo. Serum lipopro-
tein profile, apolipoprotein (apo) A-I, B and C-III and preheparin lipoprotein lipase
(LPL) were measured at baseline and at 4, 12 and 26 weeks. Lipoprotein particle pro-
file by nuclear magnetic resonance was assessed at baseline and 26 weeks. The lipo-
protein insulin resistance (LPIR) score was calculated.
Results: At 26 weeks, tirzepatide dose-dependently decreased apoB and apoC-III
levels, and increased serum preheparin LPL compared with placebo. Tirzepatide
10 and 15 mg decreased large triglyceride-rich lipoprotein particles (TRLP), small low-
density lipoprotein particles (LDLP) and LPIR score compared with both placebo and
dulaglutide. Treatment with dulaglutide also reduced apoB and apoC-III levels but
had no effect on either serum LPL or large TRLP, small LDLP and LPIR score. The
number of total LDLP was also decreased with tirzepatide 10 and 15 mg compared
with placebo. A greater reduction in apoC-III with tirzepatide was observed in
patients with high compared with normal baseline triglycerides. At 26 weeks, change
in apoC-III, but not body weight, was the best predictor of changes in triglycerides
with tirzepatide, explaining up to 22.9% of their variability.
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Conclusions: Tirzepatide treatment dose-dependently decreased levels of apoC-III
and apoB and the number of large TRLP and small LDLP, suggesting a net improve-
ment in atherogenic lipoprotein profile.
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1 | INTRODUCTION
Despite the current standard of care treatment, patients with type
2 diabetes (T2D) have a high residual risk of atherosclerotic cardiovas-
cular events.1 Most of these patients have atherogenic dyslipidaemia,
which is characterized by high levels of fasting and postprandial tri-
glycerides, low levels of high-density lipoprotein cholesterol (HDL-C)
and high levels of small low-density lipoprotein particles (LDLP) .2,3
The increase in large very-low-density lipoprotein (VLDL) particles is
at the root of the atherogenic dyslipidaemia in T2D, which is partially
secondary to insulin resistance.4 While statins reduce low-density
lipoprotein cholesterol (LDL-C) and the number of LDLP, their effect
on triglyceride-rich lipoproteins and their remnants is minimal.5 Apoli-
poprotein (apo) C-III is a key regulator of triglyceride metabolism.6–8 It
is well known that apoC-III is the inhibitor of lipoprotein lipase (LPL),
the rate-limiting enzyme of the hydrolysis.9,10 Recent data also sug-
gest that apoC-III inhibition reduces plasma triglycerides by LPL-
independent pathways by enhancing hepatic uptake of triglyceride-
rich lipoprotein (TRL) remnants via low-density lipoprotein receptor
and low density lipoprotein receptor-related protein 1 receptors in
the liver.8,11 Glucagon-like peptide-1 (GLP-1) receptor agonists have
been shown to be effective in reducing major adverse cardiac events
in T2D.12–14 Numerous mechanisms beyond glucose lowering have
been considered as possible contributors to their cardioprotective
effects. These mechanisms include weight loss, reducing blood
pressure, renal protection, and lowering chronic inflammation and
liver fat, which are all known to be associated with cardiovascular
risk.15–17 GLP-1 receptor agonists have been shown to reduce
lipoprotein and chylomicron production, as well as postprandial tri-
glycerides, VLDL cholesterol and free fatty acids,18–20 but the
magnitude of these effects is not large.
The effect of chronic treatment of glucose-dependent
insulinotropic peptide (GIP) receptor agonists on plasma lipids is not well
known.21 GIP receptor expression in adipose tissue suggests a role as a
potential regulator of dietary lipid clearance in response to postprandial
GIP secretion. Indeed, in preclinical in vivo and in vitro models, GIP
increases adipocyte LPL expression.22,23 Although the mechanisms are
not fully understood, infusion of GIP and GIP receptor antagonists in
humans suggests that GIP receptor activation increases adipose tissue
blood flow and promotes adipose tissue lipid uptake.24,25 Thus, GIP
receptor agonism in adipocytes may be a key regulator of postprandial
lipid clearance and potentially overall lipid homeostasis.
However, dual agonism of GIP and GLP-1 receptors appears to
have a greater effect on lipid and lipoprotein metabolism in vivo in
humans. We have recently shown that the effect of the dual GIP and
GLP-1 receptor agonist, tirzepatide, on plasma triglyceride is
much larger than that of the GLP-1 receptor agonist, dul-
aglutide.26 At week 26, tirzepatide at different doses and dul-
aglutide 1.5 mg did not differ in terms of changes in the
concentrations of total cholesterol, LDL-C or HDL-C.26 In the
current study, we report additional effects of tirzepatide on the
levels of apolipoproteins and lipoprotein particle subclasses mea-
sured in stored samples from the same phase 2b study of
tirzepatide in patients with T2D.
2 | MATERIALS AND METHODS
2.1 | Participants
A detailed description of participant eligibility, study design and efficacy
and safety results has been published.26 Briefly, this was a double-blind,
placebo-controlled phase 2b clinical trial, where patients were random-
ized (1:1:1:1:1:1) to receive either once-weekly subcutaneous
tirzepatide (1, 5, 10 or 15 mg), dulaglutide (1.5 mg) or placebo for
26 weeks. This trial (ClinicalTrials.gov identifier: NCT03131687) was
conducted in accordance with the Declaration of Helsinki and the Coun-
cil for International Organizations of Medical Sciences International Ethi-
cal Guidelines, the International Conference on Harmonization Good
Clinical Practices Guideline, and all other applicable laws and regulations.
All participants provided written consent prior to any procedure.
2.2 | Study procedures
Samples were collected in the fasting state. Triglycerides and LDL-C
were measured on fresh serum samples using traditional enzymatic
methods. Non-HDL-C was calculated as total cholesterol minus
HDL-C. All other measurements of apolipoproteins and lipoprotein
particle subclasses (triglyceride-rich lipoprotein particles [TRLP], LDLP
and high-density lipoprotein particles [HDLP]) were performed on
available frozen plasma EDTA or serum samples from the modified
intent-to-treat population (mITT) population. Lipoprotein particle con-
centration and average lipoprotein particle size were measured by
nuclear magnetic resonance (NMR) spectroscopy at baseline and
26 weeks (LabCorp, Burlington, NC, USA). The lipoprotein insulin
resistance (LPIR) score, a weighted combination of six lipoprotein subclass
measures (large TRLP, large HDLP, small LDLP and mean sizes of TRLP,
LDLP and HDLP), was also calculated.27 Preheparin serum LPL mass was
measured by enzyme-linked immunosorbent assay (ALPCO, Salem, NH,
2 WILSON ET AL.
USA). ApoA-I, apoB (Roche, Indianapolis, IN, USA) and apoC-III (Kamiya,
Seattle, WA, USA) were measured by immunoturbidimetry at baseline
and at 4, 12 and 26 weeks.
2.3 | Statistical analyses
Patients from the mITT (without data after study drug discontinuation or
rescue drug initiation) were included in this analysis. Baseline measure-
ments of biomarkers were analysed using analysis of variance (ANOVA)
while postbaseline measurements were analysed using mixed model with
repeated measure. Biomarkers with skewed distribution were log-
transformed at baseline prior to the analysis. A two-sided P-value of
.05 was used as significance level. Biomarkers measured by NMR
spectroscopy were analysed by analysis of covariance (ANCOVA)
values and treatment group as covariates. Large and medium LDLP
data contained many zeros, and therefore were analysed using the
Tobit regression.28
The proportion of variability in triglyceride changes explained by
potential predictors, like age, sex, baseline HbA1c, baseline body weight,
baseline triglycerides, baseline apoC-III, baseline homeostatic model
assessment of insulin resistance (HOMA-IR), HbA1c change, body
weight change, HOMA-IR change and apoC-III change, was evaluated. A
stepwise variable selection based on the Akaike information criterion
was performed on pooled data of 10 and 15 mg tirzepatide doses in
order to select the best fit model among all possibilities. ANOVA with
type-III sums of square was conducted on the output of multiple linear
regression analysis based on the final selected model to compute the
explained variability of each selected variable. The selected model and
the variability explained by each of its variables are summarized in
Table S5. Statistical analyses were performed using R 3.6.0, SAS 9.4
software (Cary, NC, USA) and GraphPad Prism 8 (San Diego, CA, USA).
3 | RESULTS
3.1 | Baseline characteristics
Baseline demographics, clinical characteristics and lipid profile were
similar across all treatment groups (Tables S1 and S2).26
3.2 | Lipid biomarker profile
The lipid profile at baseline and change from baseline at 26 weeks is pres-
ented in Table S2. Tirzepatide dose-dependently decreased triglycerides
over time compared with placebo (Figure 1A). At 26 weeks, tirzepatide
5 mg, 10 mg and 15 mg and dulaglutide decreased triglyceride levels by
28.8% (−39.0%, −16.7%; P < .001), 37.7% (−46.8%, −26.9%; P < .001),































































































F IGURE 1 Triglycerides and ApoC-III over time and change from baseline at 26 weeks. A, Change from baseline over time in triglycerides. B,
Change from baseline at 26 weeks in triglycerides. C, Change from baseline over time in ApoC-III. D, Change from baseline at 26 weeks in ApoC-III.
Data are presented as LSM actual values over time and LSM (SE) change from baseline at 26 weeks from the mITT population (placebo, n = 51;
tirzepatide 1 mg, n = 52; tirzepatide 5 mg, n = 55; tirzepatide 10 mg, n = 51; tirzepatide 15 mg, n = 53; dulaglutide 1.5 mg, n = 54). Triglycerides and
apoC-III data are presented as antilog. *P < .05 vs. baseline, †P < .05 vs. placebo, ‡P < .05 vs. dulaglutide. ApoC-III, apolipoprotein C-III; DU,
dulaglutide; PBO, placebo; TZP, tirzepatide
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(least squares mean [LSM] [95% CI]), respectively, compared with placebo
(Figure 1B). Tirzepatide 10 mg and 15 mg also decreased triglyceride levels
by 23.3% (−34.3%, −10.5%; P < .001) and 27.9% (−38.9%, −15.0%;
P < .001), respectively, compared with dulaglutide.
Tirzepatide dose-dependently also decreased apoC-III levels
over time compared with placebo (Figure 1C). At 26 weeks,
tirzepatide 5 mg, 10 mg and 15 mg and dulaglutide decreased apoC-
III levels by 25.6% (−38.0%, −10.8%; P = .002), 34.8% (−45.8%,
−21.4%; P < .001), 46.2% (−55.7%, −34.6%; P < .001) and 22.0%
(−34.9%, −6.5%; P = .007) (LSM [95% CI]), respectively, compared
with placebo (Figure 1D).
As with triglyceride and apoC-III levels, tirzepatide dose-dependently
decreased apoB levels over time compared with placebo (Figure 2A). At
26 weeks, tirzepatide 5 mg, 10 mg and 15 mg and dulaglutide decreased
apoB levels by 11.0% (−18.2%, −3.3%; P = .006), 14.8% (−21.8%, −7.2%;
P < .001), 17.4% (−24.5%, −9.5%; P < .001) and 14.1% (−21.0%, −6.7%;
P < .001) (LSM [95% CI]), respectively, compared with placebo
(Figure 2B). The magnitude of reduction in apoB levels was not signifi-
cantly different between tirzepatide and dulaglutide. Increases from base-
line in apoB and LDL-C levels were observed in the placebo group at
26 weeks (P = .019 and P = .048, respectively).
Tirzepatide 15 mg decreased LDL-C levels over time (Figure 2C).
At 26 weeks, tirzepatide 15 mg and dulaglutide decreased LDL-C
levels by 19.0% (−36.0%, −1.9%; P = .029) and 17.8% (−33.7%,
−2.0%; P = .028) (LSM [95% CI]), respectively, compared with placebo
(Figure 2D). The magnitude of reduction in LDL-C levels did not differ
between tirzepatide and dulaglutide.
Tirzepatide dose-dependently decreased non-HDL-C levels over
time (Figure S1A). At 26 weeks, tirzepatide 5 mg, 10 mg and 15 mg
and dulaglutide significantly decreased non-HDL-C levels by 16.4%
(−26.8%, −6.0%; P = .002), 21.3% (−31.9%, −10.7%; P < .001), 24.8%
(−36.0%, −13.6%; P < .001) and 17.8% (−28.3%, −7.4%; P < .001)
(LSM [95% CI]), respectively, compared with placebo (Figure S1B).
Non-HDL-C levels increased from baseline to 26 weeks in the placebo
group (P < .001).
3.3 | Lipoprotein particle subclasses
At 26 weeks, tirzepatide 5 mg, 10 mg and 15 mg decreased large
TRLP by 59.5% (−75.6%, −32.6%; P < .001), 83.4% (−90.1%, −72.1%;
P < .001) and 75.6% (−86.0%, −57.4%; P < .001) compared with pla-
cebo, and by 44.0% (−65.8%, −8.1%; P = .022), 77.0% (−86.2%,
−61.9%; P < .001) and 66.2% (−80.3%, −41.8%; P < .001) (LSM [95%
CI]) compared with dulaglutide, respectively (Figure 3A).
At 26 weeks, tirzepatide 10 mg and 15 mg also decreased small
LDLP by 23.5% (−43.3%, −3.6%; P = .021) and 32.4% (−53.7%,
−11.1%; P = .003) compared with placebo, and by 20.4% (−39.7%,
−1.1%; P = .038) and 29.3% (−50.2%, −8.5%; P = .006) (LSM [95%






















































































F IGURE 2 ApoB and LDL-C over time and change from baseline at 26 weeks. A, Change from baseline over time in ApoB. B, Change from
baseline at 26 weeks in ApoB. C, Change from baseline over time in LDL-C. D, Change from baseline at 26 weeks in LDL-C. Data are presented as
LSM actual values over time and LSM (SE) change from baseline at 26 weeks from the mITT population (placebo, n = 51; tirzepatide 1 mg, n = 52;
tirzepatide 5 mg, n = 55; tirzepatide 10 mg, n = 51; tirzepatide 15 mg, n = 53; dulaglutide 1.5 mg, n = 54). ApoB is presented as antilog. *P < .05
vs. baseline, †P < .05 vs. placebo, ‡P < .05 vs. dulaglutide. ApoB, apolipoprotein B; DU, dulaglutide; LDL-C, low-density lipoprotein cholesterol;
PBO, placebo; TZP, tirzepatide
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Percent change from baseline to week 26 in all lipoprotein parti-
cle concentrations and size are presented in Table S3. At 26 weeks,
tirzepatide 10 and 15 mg decreased the mean TRLP size compared
with placebo and dulaglutide. Tirzepatide 5 mg, 10 mg and 15 mg
decreased total LDLP concentrations compared with placebo,
whereas large LDLP concentrations and mean LDLP size were
increased compared with dulaglutide. Total and large LDLP concentra-
tions increased in the placebo group. Tirzepatide 10 and 15 mg
decreased the overall LPIR score by 33.5% and 31.7% compared with
placebo and dulaglutide, respectively. At 26 weeks, tirzepatide 15 mg
decreased total and small HDLP compared with both placebo and dul-
aglutide. HDL-C and apoA-I levels did not change with tirzepatide.
3.4 | Preheparin serum LPL mass
At 26 weeks, preheparin serum LPL mass dose-dependently increased
from baseline with tirzepatide 5 mg, 10 mg and 15 mg by 9.4 ng/mL
(2.0, 16.9; P = .013), 10.1 ng/mL (2.5, 17.7; P = .009) and 11.2 ng/mL
(3.2, 19.3; P = .006) (LSM [95% CI]), respectively, compared with pla-
cebo (Figure 4).
3.5 | Lipoprotein profile in baseline triglyceride
subgroups
The dose-dependent decrease in triglycerides and apoC-III with
tirzepatide 5 mg, 10 mg and 15 mg was larger in patients with base-
line triglyceride levels greater than or equal to 150 mg/dL compared
with those with baseline triglycerides of less than 150 mg/dL. The
highest dose of tirzepatide decreased triglyceride levels by 23%
(Figure 5A) and apoC-III by 38% from baseline (Figure 5B) in those
with triglycerides of less than 150 mg/dL compared with 43%
(Figure 5C) and 47% (Figure 5D), respectively, for those with base-
line triglycerides greater than or equal to 150 mg/dL. In patients
with high baseline triglyceride levels (>150 mg/dL), the proportion
of those reaching triglyceride levels of less than 100 mg/dL at
26 weeks was significantly higher for tirzepatide 10 mg and 15 mg
compared with dulaglutide (25%, 15% and 9%, respectively;
Table S4).
At 26 weeks, the effect of tirzepatide on LDL-C levels was similar
in patients with baseline triglycerides of both less than and greater
than or equal to 150 mg/dL (Figure S2A,C), whereas tirzepatide
10 mg and 15 mg resulted in a larger reduction of small LDLP in
patients with baseline triglycerides greater than or equal to 150 mg/
dL (Figure S2B,D).
3.6 | Predictors of triglyceride changes
Based on the variable selection procedure described in the Methods,
body weight change, HbA1c change, apoC-III change, baseline body
weight and sex entered the regression model explaining triglyceride
changes (Table S5). Changes in apoC-III levels explained up to 22.9%
of the variability in triglycerides in the two highest tirzepatide dose
groups, whereas tirzepatide-induced weight loss only explained up
to 4.4%.
4 | DISCUSSION
In this paper, we present the effects of the novel dual GIP and GLP-1
receptor agonist, tirzepatide, on additional lipid and lipoprotein bio-
markers measured in our randomized, double-blind, controlled phase
Actual value LSM (SE), nmol/L Placebo    TZP 1 mg   TZP 5 mg   TZP 10 mg   TZP 15 mg   DU 1.5 mg
Baseline: 6.4 (1.2)    4.7 (1.2)      5.2 (1.2)      6.0 (1.2)         5.1 (1.2)        4.6 (1.2)
Actual value LSM (SE), nmol/L Placebo         TZP 1 mg      TZP 5 mg       TZP 10 mg    TZP 15 mg     DU 1.5 mg







































































F IGURE 3 Major lipoprotein particle subclass changes at 26 weeks. A, Percent change from baseline at 26 weeks in large TRLP. B, Percent
change from baseline at 26 weeks in small LDLP. Data are presented as actual value LSM (SE) at baseline and LSM % change from baseline (95%
CI) at 26 weeks from the mITT population (placebo, n = 51; tirzepatide 1 mg, n = 52; tirzepatide 5 mg, n = 55; tirzepatide 10 mg, n = 51;
tirzepatide 15 mg, n = 53; dulaglutide 1.5 mg, n = 54). Large TRLP is presented as antilog. Note that large TRLP includes ‘large’ and ‘very large’
particles. *P < .05 vs. baseline, †P < .05 vs. placebo, ‡P < .05 vs. dulaglutide. DU, dulaglutide; LDLP, low-density lipoprotein particles; TRLP,
triglyceride-rich lipoprotein particles; TZP, tirzepatide
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2b study in patients with T2D.26 Overall, tirzepatide dose-
dependently decreased triglyceride, apoB and apoC-III levels over
time and decreased the number of large TRLP and small LDLP. The
most robust changes were observed with the highest doses of
tirzepatide (10 and 15 mg).
Serum triglycerides had an average reduction of 31% and 35%
and apoC-III had an average reduction of 32% and 44% from baseline
with the two highest doses of tirzepatide (10 and 15 mg, respectively).
These changes are remarkable compared with those reported for
effective triglyceride-lowering drugs, like fenofibrate, in patients with
T2D (triglycerides were reduced by 26% and apoC-III by 20%).7,29 Up
to 25% of the patients with high baseline triglyceride levels treated
with tirzepatide reached triglyceride levels of less than 100 mg/dL at
26 weeks. Although apoB levels also decreased dose-dependently,
the percent change from baseline was 11% compared with 35% for
triglycerides at the highest dose of tirzepatide. This finding implies
that the increase in triglyceride lipolysis per particle is greater than
the decrease in the number of apoB-containing particles, as suggested
by the presence of a significant correlation between triglyceride and
apoB levels at baseline (r = 0.29, P = .01), but not between changes in
triglyceride and apoB levels at 26 weeks (r = 0.24, P = .04). The discor-
dant changes between triglyceride and apoB levels are further
supported by the marked reduction in the numbers of large TRLP and
the average size of TRLP at the two highest doses of tirzepatide.
Therefore, tirzepatide treatment results in smaller-sized VLDL parti-




























Actual value LSM (SE), ng/mL Placebo     TZP 1 mg   TZP 5 mg   TZP 10 mg   TZP 15 mg   DU 1.5 mg







F IGURE 4 Change from baseline to week
26 in preheparin serum LPL mass. Data are
presented as actual value LSM (SE) at baseline and
LSM (SE) change from baseline at 26 weeks from
the mITT population (placebo, n = 51; tirzepatide
1 mg, n = 52; tirzepatide 5 mg, n = 55; tirzepatide
10 mg, n = 51; tirzepatide 15 mg, n = 53;
dulaglutide 1.5 mg, n = 54). *P < .05 vs. baseline,
†P < .05 vs. placebo. DU, dulaglutide; LPL,
lipoprotein lipase; TZP, tirzepatide
Actual value LSM (SE), mg/dL Placebo       TZP 1 mg    TZP 5 mg   TZP 10 mg   TZP 15 mg   DU 1.5 mg
Baseline: 122.0 (5.6)   106.0 (4.9)    114.9 (5.3)   112.6 (6.1)    109.3 (5.7)    106.0 (4.9)
Serum triglycerides <150 mg/dL
Triglycerides (n = 145)
0.0 0.5 1.0 1.5
Geometric mean fold change from baseline Geometric mean fold change from baseline









Actual value LSM (SE), mg/dL Placebo    TZP 1 mg   TZP 5 mg   TZP 10 mg   TZP 15 mg   DU 1.5 mg
Baseline:  10.5 (1.1)   9.5 (1.1)      9.6 (1.1)       9.9 (1.1)       10.1 (1.1)       9.4 (1.1) 
Serum triglycerides <150 mg/dL
Plasma apoC-III (n = 136)








Actual value LSM (SE), mg/dL Placebo        TZP 1 mg    TZP 5 mg     TZP 10 mg    TZP 15 mg   DU 1.5 mg
Baseline:  229.0 (16.3)  217.9 (15.0)  245.6 (16.5)  220.0 (13.6)   250.6 (16.3)  220.0 (15.0) 
Serum triglycerides ≥150 mg/dL
Triglycerides (n = 161)









Actual value LSM (SE), mg/dL Placebo    TZP 1 mg   TZP 5 mg   TZP 10 mg   TZP 15 mg   DU 1.5 mg
Baseline:  17.8 (1.1)  15.2 (1.1)     18.9 (1.1)    13.7 (1.1)       17.3 (1.1)      16.8 (1.1) 
Serum triglycerides ≥150 mg/dL
Plasma apoC-III (n = 150)














F IGURE 5 Change from baseline to week 26 in triglycerides and ApoC-III in patients with A and B, baseline triglycerides <150 mg/dL,
respectively, and with C and D, baseline triglycerides ≥150 mg/dL, respectively. Data are presented as LSM fold change vs. baseline from the
mITT population (placebo, n = 51; tirzepatide 1 mg, n = 52; tirzepatide 5 mg, n = 55; tirzepatide 10 mg, n = 51; tirzepatide 15 mg, n = 53;
dulaglutide 1.5 mg, n = 54). *P < .05 vs. baseline, †P < .05 vs. placebo, ‡P < .05 vs. dulaglutide. apoC-III, apolipoprotein C-III; DU, dulaglutide; TZP,
tirzepatide
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generating small dense LDL,30 thus shifting the LDL distribution
towards less atherogenic LDLP. Although postheparin hepatic lipase
(HL) activity was not measured in this study, GIP receptor-specific
antagonism has been shown to suppress HL activity in mice in vivo,31
whereas postprandial GIP response has been suggested to increase
HL activity in vivo in humans.32 HL hydrolyses triglycerides and phos-
pholipids in apoB-containing lipoproteins and HDL, resulting in the
formation of small LDLP and HDLP. Indeed, HL-deficient subjects
have large buoyant LDLP and large-size HDLP.33 Treatment with
tirzepatide reduced both small LDLP and HDLP compared with dul-
aglutide, despite no differences being observed in either the LDL-C or
HDL-C levels between the two treatments. These changes in lipopro-
tein subclass distribution may be secondary to improved insulin sensi-
tivity with tirzepatide.34 Taken together, the significant reductions in
small LDLP, non-HDL-C and apoB levels, in addition to reductions of
triglycerides and apoC-III, point towards an overall less atherogenic
lipoprotein profile in patients with T2D treated with tirzepatide.
In this study, we also observed a dose-dependent increase in pre-
heparin plasma LPL mass during tirzepatide therapy compared with
placebo, in line with previous data, demonstrating that GIP induces
LPL activity in vitro and in vivo.22,23 Notably, GIP enhances the vaso-
dilation and capillary recruitment, resulting in an increased uptake of
fatty acids from circulating triglycerides. This finding supports the
increased lipolytic capacity and reduction of triglyceride levels
observed with tirzepatide. However, we found no correlation
between changes in preheparin LPL mass and changes in plasma tri-
glyceride levels (r = −0.10, P = .38). This may be attributed to two cau-
ses. First, preheparin LPL in circulation only represents a trivial
amount of the actual enzyme at endothelial surfaces. Second, even
heparin-releasable LPL activity may not completely reflect the true
activity of LPL at its actual sites of action. The lack of correlation
between changes in preheparin LPL mass and changes in triglycerides
could also suggest a role of other determinants of triglyceride concen-
trations, such as apoC-III. Indeed, triglyceride clearance rates in both
the fasting and postprandial states have been shown to be closely
linked to plasma apoC-III levels, but not related to postheparin plasma
LPL activity.35,36 The reduction of apoC-III levels with tirzepatide is
unlikely to be explained by direct GIP receptor agonism in hepato-
cytes because GIP receptors do not appear to be expressed in the
liver.37,38 A direct effect of tirzepatide on intestinal GIP receptors
could theoretically reduce intestinal apoC-III production, but this also
seems unlikely to explain reduced fasting apoC-III levels. Indirect
mechanisms of tirzepatide on GIP receptors may be partially responsi-
ble for the effect of tirzepatide on apoC-III levels. As this is a descrip-
tive study, we cannot exclude the potential contribution of a reduced
large VLDL production rate to large VLDL and decreased triglycerides.
A kinetic study using stable isotopes is warranted to elucidate the role
of tirzepatide in the metabolism of fasting and postprandial TRLs in
humans.
In the current study, the magnitude of reduction of triglyceride
and apoC-III levels was very similar at all efficacious doses of
tirzepatide in patients with either normal (<150 mg/dL) or elevated
baseline triglycerides. We also observed strong correlations between
changes in apoC-III and changes in triglycerides for all dose groups,
with an r value of 0.69 for the two combined highest doses. Finally,
changes in apoC-III levels were the strongest predictor of changes in
serum triglycerides with tirzepatide, explaining 23% of the variance
in a regression model that also included changes in HbA1c and body
weight among other variables. This is not unexpected, as apoC-III is
critical for triglyceride metabolism, through inhibition of LPL activity
and impairment of triglyceride-rich lipoprotein clearance by promoting
the uptake of TFL remnants by the liver.8,36 Weight loss with bariatric
surgery is consistently accompanied not only by HbA1c reduction, but
has also resulted in markedly reduced plasma triglycerides and apoC-
III, and this decrease was accompanied by a redistribution of apoC-III
from triglyceride-rich lipoproteins to HDL.39 However, although
tirzepatide resulted in better glucose control and greater weight loss
than dulaglutide, the multiple linear regression analysis indicated that
tirzepatide-induced weight loss only explained a small portion of the
variability in triglycerides.
This raises the issue of why apoC-III was reduced by tirzepatide
in these subjects with diabetes. It is well known that the expression of
apoC-III is regulated by both plasma glucose and insulin, but in oppo-
site directions.7 In fact, the transcription rate of apoC-III has been
reported to be inhibited by insulin via PPAR-α and FXR,8,40,41 whereas
glucose has been shown to stimulate expression of apoC-III via HNF-
4α and ChREBP.42 However, even though insulin resistance and T2D
hyperglycaemia and hyperinsulinemia co-exist, VLDL overproduction
and hypertriglyceridaemia result from both hyperglycaemia and the
inability of insulin to suppress apoC-III expression secondary to the
insensitivity of FoxO1 signalling.43–45 Plasma apoC-III concentrations
are known to be increased in subjects with T2D and in those with
insulin resistance,46 and recently it was reported that apoC-III metab-
olism is disturbed in those subjects.47 The apoC-III secretion rate mea-
sured using the stable isotope leucine was markedly higher in subjects
with T2D than in body mass index-matched non-diabetic subjects.
Treatment with liraglutide (1.8 mg/day) for 16 weeks reduced the
apoC-III concentration by 14%, and changes in plasma apoC-III were
significantly associated with changes in HbA1c, supporting the role of
glucose homeostasis as a regulator of apoC-III levels and apoC-III pro-
duction.47 In the current study, changes in apoC-III levels were also
significantly associated with changes in HbA1c at the two highest
doses (r = 0.33, P = .005), but not with changes in HOMA-IR
(r = 0.17, P = .19).
This study had limitations. First, because this was a post hoc anal-
ysis of additional biomarkers measured in stored samples, the sample
size calculated for the original clinical trial could be inappropriate for
these analyses. However, results were similar when the two highest
dose groups of tirzepatide were analysed as combined, considering
that they had similar efficacy. Second, all lipids, lipoproteins and apoli-
poproteins were measured on a single fasting plasma sample at differ-
ent times of the 26-week study. However, static measurements in the
fasting state remain descriptive and do not reveal underlying mecha-
nisms, therefore, stable isotope kinetic studies in the postprandial
state are needed to better understand the mechanistic dynamics of
the lipid changes during tirzepatide therapy.
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In conclusion, the dose-dependent decrease in apoC-III levels
appears to partially explain the dose-dependent reduction in triglycer-
ides following tirzepatide treatment, independently of weight loss.
Moreover, the reduction in the number of large TRLP and small LDLP
and apoB levels is consistent with a net improvement in insulin sensi-
tivity and atherogenic lipoprotein profile following tirzepatide treat-
ment. The planned cardiovascular outcomes study SURPASS-CVOT
(NCT04255433) should provide definitive data on the potential fur-
ther cardiovascular benefit of the dual GIP and GLP-1 receptor ago-
nist, tirzepatide, above and beyond treatment with a GLP-1 receptor
agonist alone.
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